😷🙄🇬🇧😷🙄🇬🇧😷🙄🇬🇧
Just back from chemo unit - first denosumab injection.
Most of the staff were ‘non white’ ~ they might not even have had A level English! Shock, horror!
But they did a superb job.
#nhs
Just back from chemo unit - first denosumab injection.
Most of the staff were ‘non white’ ~ they might not even have had A level English! Shock, horror!
But they did a superb job.
#nhs
October 15, 2025 at 11:42 AM
😷🙄🇬🇧😷🙄🇬🇧😷🙄🇬🇧
Just back from chemo unit - first denosumab injection.
Most of the staff were ‘non white’ ~ they might not even have had A level English! Shock, horror!
But they did a superb job.
#nhs
Just back from chemo unit - first denosumab injection.
Most of the staff were ‘non white’ ~ they might not even have had A level English! Shock, horror!
But they did a superb job.
#nhs
Denosumab found to have higher rates of hypocalcemia and hypophosphatemia than zoledronate in patients with advanced CKD.
www.ajkd.org/article/S027...
www.ajkd.org/article/S027...
Risks of Hypocalcemia and Other Bone Mineral Disorders for Denosumab Versus Zoledronate Across the Spectrum of Kidney Function: A Target Trial Emulation
Denosumab, an osteoporosis medication, may induce hypocalcemia, secondary hyperparathyroidism
(SHPT), and hypophosphatemia. We studied these risks compared with zoledronate and
whether the risks diffe...
www.ajkd.org
September 28, 2026 at 10:41 PM
Denosumab found to have higher rates of hypocalcemia and hypophosphatemia than zoledronate in patients with advanced CKD.
www.ajkd.org/article/S027...
www.ajkd.org/article/S027...
#DragiWebdo n°487 : OMA (HAS/SPILF), stéatose/MASLD (recos US), risque CV/VIH (recos US), uvéites, COVID, zilebesiran, dénosumab, inquiétude parentale
www.medicalement-geek.com/2025/06/drag...
www.medicalement-geek.com/2025/06/drag...
Dragi Webdo n°487 : OMA (HAS/SPILF), stéatose/MASLD (recos US), risque CV/VIH (recos US), uvéites, COVID, zilebesiran, dénosumab, inquiétude parentale
Dragi Webdo n°487 : OMA (HAS/SPILF), stéatose/MASLD (recos US), risque CV/VIH (recos US), uvéites, COVID, zilebesiran, dénosumab, inquiétude parentale
www.medicalement-geek.com
June 2, 2025 at 8:05 PM
#DragiWebdo n°487 : OMA (HAS/SPILF), stéatose/MASLD (recos US), risque CV/VIH (recos US), uvéites, COVID, zilebesiran, dénosumab, inquiétude parentale
www.medicalement-geek.com/2025/06/drag...
www.medicalement-geek.com/2025/06/drag...
Bombshell from @annalsofim.bsky.social
#Denosumab or Prolia compared to Oral bisphosphonates in dialysis
Target Trial Emulation, from Japan
45% Less fractures
36% higher MACE!
www.acpjournals.org/doi/10.7326/... 🔒
#Denosumab or Prolia compared to Oral bisphosphonates in dialysis
Target Trial Emulation, from Japan
45% Less fractures
36% higher MACE!
www.acpjournals.org/doi/10.7326/... 🔒
Cardiovascular Safety and Fracture Prevention Effectiveness of Denosumab Versus Oral Bisphosphonates in Patients Receiving Dialysis: A Target Trial Emulation: Annals of Internal Medicine: Vol 0, No 0
Background: Dialysis patients have high rates of fracture morbidity, but evidence on optimal management strategies for osteoporosis is scarce. Objective: To determine the risk for cardiovascular event...
www.acpjournals.org
January 6, 2025 at 11:18 PM
Bombshell from @annalsofim.bsky.social
#Denosumab or Prolia compared to Oral bisphosphonates in dialysis
Target Trial Emulation, from Japan
45% Less fractures
36% higher MACE!
www.acpjournals.org/doi/10.7326/... 🔒
#Denosumab or Prolia compared to Oral bisphosphonates in dialysis
Target Trial Emulation, from Japan
45% Less fractures
36% higher MACE!
www.acpjournals.org/doi/10.7326/... 🔒
Denosumab for #osteoporosis in older adults in long-term care: A randomized trial. #gerosky #endosky agsjournals.onlinelibrary.wiley.com/doi/10.1111/...
November 19, 2024 at 8:13 PM
Denosumab for #osteoporosis in older adults in long-term care: A randomized trial. #gerosky #endosky agsjournals.onlinelibrary.wiley.com/doi/10.1111/...
Still vertical. Had denosumab jab y/day ( for cancery bones) so that was 24 hrs i won’t get back!
Halley sends purrs
Halley sends purrs
March 5, 2026 at 5:32 PM
Still vertical. Had denosumab jab y/day ( for cancery bones) so that was 24 hrs i won’t get back!
Halley sends purrs
Halley sends purrs
#DragiWebdo n°431 : Opioïdes (chutes, grossesse), ARN interférents/HTA, dénosumab/diabète, BPCO, Behçet
www.medicalement-geek.com/2024/02/drag...
www.medicalement-geek.com/2024/02/drag...
Dragi Webdo n°431 : Opioïdes (chutes, grossesse), ARN interférents/HTA, dénosumab/diabète, BPCO, Behçet
Dragi Webdo n°431 : Opioïdes (chutes, grossesse), ARN interférents/HTA, dénosumab/diabète, BPCO, Behçet
www.medicalement-geek.com
February 28, 2024 at 10:00 PM
#DragiWebdo n°431 : Opioïdes (chutes, grossesse), ARN interférents/HTA, dénosumab/diabète, BPCO, Behçet
www.medicalement-geek.com/2024/02/drag...
www.medicalement-geek.com/2024/02/drag...
Now even the US FDA getting into target trial emulations (TTE)
pubmed.ncbi.nlm.nih.gov/39556837/
does denosumab aka D-mab cause hypocalcemia?
of course - duh - see @kdjhaveri.bsky.social on @ajkd.bsky.social blog in 2012 ajkdblog.org/2012/10/04/d...
1/
pubmed.ncbi.nlm.nih.gov/39556837/
does denosumab aka D-mab cause hypocalcemia?
of course - duh - see @kdjhaveri.bsky.social on @ajkd.bsky.social blog in 2012 ajkdblog.org/2012/10/04/d...
1/
The Effect of Denosumab on Risk for Emergently Treated Hypocalcemia by Stage of Chronic Kidney Disease : A Target Trial Emulation - PubMed
U.S. Food and Drug Administration.
pubmed.ncbi.nlm.nih.gov
November 30, 2024 at 6:39 PM
Now even the US FDA getting into target trial emulations (TTE)
pubmed.ncbi.nlm.nih.gov/39556837/
does denosumab aka D-mab cause hypocalcemia?
of course - duh - see @kdjhaveri.bsky.social on @ajkd.bsky.social blog in 2012 ajkdblog.org/2012/10/04/d...
1/
pubmed.ncbi.nlm.nih.gov/39556837/
does denosumab aka D-mab cause hypocalcemia?
of course - duh - see @kdjhaveri.bsky.social on @ajkd.bsky.social blog in 2012 ajkdblog.org/2012/10/04/d...
1/
Denosumab Triggers Paradoxical Hungry Bone Syndrome-Like State in Multiple Myeloma Patient | "A patient with multiple myeloma developed a severe, prolonged hypocalcemia and hypophosphatemia after a single dose of denosumab". Read more: https://bit.ly/4wPvlID
Denosumab Triggers Paradoxical Hungry Bone Syndrome-Like State in Multiple Myeloma Patient - Endocrine News
A recent study from JCEM Case Reports reveals that denosumab, a human monoclonal antibody widely used to prevent fractures, can cause a rare “hungry bone syndrome-like state” even in purely bone-destr...
bit.ly
July 18, 2026 at 8:19 PM
Denosumab Triggers Paradoxical Hungry Bone Syndrome-Like State in Multiple Myeloma Patient | "A patient with multiple myeloma developed a severe, prolonged hypocalcemia and hypophosphatemia after a single dose of denosumab". Read more: https://bit.ly/4wPvlID
This is denosumab … i will mention it to nurse next jab . tho they weigh me so they will see for themselves.
Luckily, a small glass of wine is recommended as an appetiser and I am soo there for that!
Luckily, a small glass of wine is recommended as an appetiser and I am soo there for that!
February 21, 2026 at 2:39 PM
This is denosumab … i will mention it to nurse next jab . tho they weigh me so they will see for themselves.
Luckily, a small glass of wine is recommended as an appetiser and I am soo there for that!
Luckily, a small glass of wine is recommended as an appetiser and I am soo there for that!
Denosumab is not a fire-and-forget injection.
Missing or stopping it without a plan can be followed by rapid bone loss and spine fractures.
Whoever gives the first dose owns the question of who gives the next one.
Missing or stopping it without a plan can be followed by rapid bone loss and spine fractures.
Whoever gives the first dose owns the question of who gives the next one.
September 26, 2026 at 8:30 PM
Denosumab is not a fire-and-forget injection.
Missing or stopping it without a plan can be followed by rapid bone loss and spine fractures.
Whoever gives the first dose owns the question of who gives the next one.
Missing or stopping it without a plan can be followed by rapid bone loss and spine fractures.
Whoever gives the first dose owns the question of who gives the next one.
Here atm for denosumab jab.
December 10, 2025 at 8:48 AM
Here atm for denosumab jab.
Tror inte det är virus. Känner nog bara av Denosumab. Sover och sover.
Så jag har bokat av nyårsmiddag och blir hemma. Och det är egentligen skönt.
Gott Nytt på er! Kikar väl in när jag orkar.
Så jag har bokat av nyårsmiddag och blir hemma. Och det är egentligen skönt.
Gott Nytt på er! Kikar väl in när jag orkar.
Viruskänsla igen
Hoppas att det stannar här
Vaccinerad & redo
Hoppas att det stannar här
Vaccinerad & redo
a woman says we 're gonna have to fight in a netflix advertisement
Alt: a woman says we 're gonna have to fight in a netflix advertisement
media.tenor.com
December 31, 2025 at 1:45 PM
Tror inte det är virus. Känner nog bara av Denosumab. Sover och sover.
Så jag har bokat av nyårsmiddag och blir hemma. Och det är egentligen skönt.
Gott Nytt på er! Kikar väl in när jag orkar.
Så jag har bokat av nyårsmiddag och blir hemma. Och det är egentligen skönt.
Gott Nytt på er! Kikar väl in när jag orkar.
#Medsky🧪#pharmasky
@fda.gov approves second biosimilars to #Prolia & #Xgeva ( #denosumab) Denosumab is a type of targeted Drug #monoclonalantibody. It is for secondary bone cancer Tx . bnf.nice.org.uk/drugs/denosu...
www.accessdata.fda.gov/drugsatfda_d...
@fda.gov approves second biosimilars to #Prolia & #Xgeva ( #denosumab) Denosumab is a type of targeted Drug #monoclonalantibody. It is for secondary bone cancer Tx . bnf.nice.org.uk/drugs/denosu...
www.accessdata.fda.gov/drugsatfda_d...
February 14, 2025 at 9:30 PM
#Medsky🧪#pharmasky
@fda.gov approves second biosimilars to #Prolia & #Xgeva ( #denosumab) Denosumab is a type of targeted Drug #monoclonalantibody. It is for secondary bone cancer Tx . bnf.nice.org.uk/drugs/denosu...
www.accessdata.fda.gov/drugsatfda_d...
@fda.gov approves second biosimilars to #Prolia & #Xgeva ( #denosumab) Denosumab is a type of targeted Drug #monoclonalantibody. It is for secondary bone cancer Tx . bnf.nice.org.uk/drugs/denosu...
www.accessdata.fda.gov/drugsatfda_d...
🧵 Osteoporosis treatment with bisphosphonates or denosumab over several years was associated with reductions in fractures.
Learn more about the published evidence on the benefits and harms of screening for #osteoporosis in this USPSTF review.
🔗 ja.ma/4alkA6C
Learn more about the published evidence on the benefits and harms of screening for #osteoporosis in this USPSTF review.
🔗 ja.ma/4alkA6C
January 20, 2025 at 3:26 PM
🧵 Osteoporosis treatment with bisphosphonates or denosumab over several years was associated with reductions in fractures.
Learn more about the published evidence on the benefits and harms of screening for #osteoporosis in this USPSTF review.
🔗 ja.ma/4alkA6C
Learn more about the published evidence on the benefits and harms of screening for #osteoporosis in this USPSTF review.
🔗 ja.ma/4alkA6C
FDA Approves 2 Denosumab Biosimilars for Osteoporosis and Cancer-Related Bone Disease #oncology www.onclive.com/view/fda-app...
FDA Approves 2 Denosumab Biosimilars for Osteoporosis and Cancer-Related Bone Disease
The FDA has approved 2 denosumab biosimilars for all indications of their respective reference medications.
www.onclive.com
March 4, 2025 at 3:56 PM
FDA Approves 2 Denosumab Biosimilars for Osteoporosis and Cancer-Related Bone Disease #oncology www.onclive.com/view/fda-app...
4w Denosumab or 12w
The efficacy results of the REDUSE study are not mature yet but the tox results are in
Less drug - fewer tox events
ONJ all grades 8.1 vs 5.2%
#SABCS24
The efficacy results of the REDUSE study are not mature yet but the tox results are in
Less drug - fewer tox events
ONJ all grades 8.1 vs 5.2%
#SABCS24
December 11, 2024 at 1:33 PM
4w Denosumab or 12w
The efficacy results of the REDUSE study are not mature yet but the tox results are in
Less drug - fewer tox events
ONJ all grades 8.1 vs 5.2%
#SABCS24
The efficacy results of the REDUSE study are not mature yet but the tox results are in
Less drug - fewer tox events
ONJ all grades 8.1 vs 5.2%
#SABCS24
🦴 A study compared #cardiovascular risks and #fracture prevention benefits of denosumab versus oral bisphosphonates in patients on #dialysis. #nephrology #nephsky
Cardiovascular Safety, Efficacy of Denosumab Versus Oral Bisphosphonates in Patients on Dialysis | Docwire News
A study compared the risk for cardiovascular events and fracture prevention benefits of denosumab versus oral bisphosphonates among dialysis-dependent patients.
www.docwirenews.com
March 19, 2025 at 4:54 PM
🦴 A study compared #cardiovascular risks and #fracture prevention benefits of denosumab versus oral bisphosphonates in patients on #dialysis. #nephrology #nephsky
Therapeutic Strategies of Denosumab Sequential Therapy: A Four-Armed Randomized Controlled Trial
ascpt.onlinelibrary.wiley.com/doi/abs/10.1...
ascpt.onlinelibrary.wiley.com/doi/abs/10.1...
Therapeutic Strategies of Denosumab Sequential Therapy: A Four‐Armed Randomized Controlled Trial
After denosumab discontinuation, the rebound effect can lead to rapid bone loss and increased fracture risk. Identifying effective sequential therapies after denosumab discontinuation is crucial to m...
ascpt.onlinelibrary.wiley.com
October 11, 2025 at 12:58 PM
Therapeutic Strategies of Denosumab Sequential Therapy: A Four-Armed Randomized Controlled Trial
ascpt.onlinelibrary.wiley.com/doi/abs/10.1...
ascpt.onlinelibrary.wiley.com/doi/abs/10.1...
In postmenopausal women with severe osteoporosis, adding romosozumab to long-term denosumab treatment led to numerically greater BMD improvement & significantly improved P1nP compared to patients remaining on denosumab alone
Arthritis & Rheumatology
doi.org/10.1002/art....
#Medsky
Arthritis & Rheumatology
doi.org/10.1002/art....
#Medsky
December 10, 2025 at 9:54 PM
In postmenopausal women with severe osteoporosis, adding romosozumab to long-term denosumab treatment led to numerically greater BMD improvement & significantly improved P1nP compared to patients remaining on denosumab alone
Arthritis & Rheumatology
doi.org/10.1002/art....
#Medsky
Arthritis & Rheumatology
doi.org/10.1002/art....
#Medsky
Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis. G Adami et al. Arthritis Rheumatol. G Adami et al. 1 Dec 2025 shorturl.at/GefdX … romosozumab can retain its anabolic potential when introduced in combination with denosumab
December 13, 2025 at 8:48 AM
Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis. G Adami et al. Arthritis Rheumatol. G Adami et al. 1 Dec 2025 shorturl.at/GefdX … romosozumab can retain its anabolic potential when introduced in combination with denosumab
Trends in serum phosphate, calcium, and parathyroid hormone levels according to renal function following denosumab. JH Lee et al. Osteoporos Int 12 July 2025 shorturl.at/rbVLq …despite initial fluctuation, denosumab might be a safe for CKD patients but with appropriate monitoring and management
July 15, 2025 at 6:58 AM
Trends in serum phosphate, calcium, and parathyroid hormone levels according to renal function following denosumab. JH Lee et al. Osteoporos Int 12 July 2025 shorturl.at/rbVLq …despite initial fluctuation, denosumab might be a safe for CKD patients but with appropriate monitoring and management
May Arthritis & Rheumatology Clinical Connections
Romosozumab + Denosumab Comb. Therapy After Denosumab in Postmenopausal Osteoporosis
Risk Factors for Relapse in ANCA-Associated Vasculitis Among Patients w/ Relapse Remission Induction w/ RTX
acrjournals.onlinelibrary.wiley.com/doi/epdf/10....
Romosozumab + Denosumab Comb. Therapy After Denosumab in Postmenopausal Osteoporosis
Risk Factors for Relapse in ANCA-Associated Vasculitis Among Patients w/ Relapse Remission Induction w/ RTX
acrjournals.onlinelibrary.wiley.com/doi/epdf/10....
May 3, 2026 at 8:39 PM
May Arthritis & Rheumatology Clinical Connections
Romosozumab + Denosumab Comb. Therapy After Denosumab in Postmenopausal Osteoporosis
Risk Factors for Relapse in ANCA-Associated Vasculitis Among Patients w/ Relapse Remission Induction w/ RTX
acrjournals.onlinelibrary.wiley.com/doi/epdf/10....
Romosozumab + Denosumab Comb. Therapy After Denosumab in Postmenopausal Osteoporosis
Risk Factors for Relapse in ANCA-Associated Vasculitis Among Patients w/ Relapse Remission Induction w/ RTX
acrjournals.onlinelibrary.wiley.com/doi/epdf/10....
Denosumab for #osteoporosis in older adults in long‐term care: A randomized trial
"...Participants with #multimorbidity, dysmobility, and #cognitive impairment were not excluded..."
#LTC #Geriatrics #MedSky #Health
"...Participants with #multimorbidity, dysmobility, and #cognitive impairment were not excluded..."
#LTC #Geriatrics #MedSky #Health
November 12, 2024 at 9:02 PM
Denosumab for #osteoporosis in older adults in long‐term care: A randomized trial
"...Participants with #multimorbidity, dysmobility, and #cognitive impairment were not excluded..."
#LTC #Geriatrics #MedSky #Health
"...Participants with #multimorbidity, dysmobility, and #cognitive impairment were not excluded..."
#LTC #Geriatrics #MedSky #Health